Elon Musk Joins Twitter Conversation About Psychedelics: A Debate On Empathy
Elon Musk continues touting the benefits of psychedelics, from his live interview at CodeCon2021 to his most recent tweets endorsing those
MindMed’s Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.
Filament Health Shares Q3 2022 Results, On Road To Becoming Industry’s Natural Psilocybin Supplier
Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022.
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu
Atai Life Sciences’ Q3 2022 Financials & Business Update, ‘Strong Capability To Execute’
Clinical-stage psychedelics company atai Life Sciences N.V. (NASDAQ: ATAI) reported its financial results for the quarter ended September 30, 2022 and shared business developments.
Psychedelics Investment Holder Blackhawk Growth Hosts Meeting For Potential Subsidiary Spin-Out
Blackhawk Growth Corp. (OTCMKTS: BLRZF), an investment holding company focused on acquiring and developing high-growth companies in the health, cannabis and psychedelics sectors in the US and Canada, announced it intends to complete a spin-out transaction of its wholly-owned subsidiaries MindBio Therapeutics Pty. Ltd.
Psyched: Brock Pierce Joins Psychedelic VC, Colorado’s Psychedelics Legalization, Zappy Zapolin’s Open Letter & More
Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'
EXCLUSIVE: Insider’s Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
(Part four of a four-part series)
See previous stories in this series:
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial
Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD).
COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term’s Highlights
Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.